Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

11.70 +0.05 (+0.47%)

Delayed Quote Updated: 10:04 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

February 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

February 01, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

January 13, 2022

Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

January 13, 2022

RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on...

Via Benzinga

Expert Ratings For Enanta Pharmaceuticals ↗

November 08, 2021

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ra...

Via Benzinga

Earnings Scheduled For February 8, 2022 ↗

February 08, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

Via Benzinga

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

January 06, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

7 A-Rated Biotechs to Buy for the Long Run ↗

December 03, 2021

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Via InvestorPlace

Where Enanta Pharmaceuticals Stands With Analysts ↗

November 24, 2021

Over the past 3 months, 11 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:

Via Benzinga

56 Biggest Movers From Yesterday ↗

November 24, 2021

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating...

Via Benzinga

Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transcript ↗

November 22, 2021

ENTA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

November 22, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

52 Biggest Movers From Friday ↗

November 22, 2021

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...

Via Benzinga

Earnings Scheduled For November 22, 2021 ↗

November 22, 2021

Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya...

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 19, 2021

Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares...

Via Benzinga

Enanta Pharmaceuticals's Earnings: A Preview ↗

November 19, 2021

Enanta Pharmaceuticals (NASDAQ:ENTA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement....

Via Benzinga

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗

November 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...

Via Benzinga

Safety Signals Force Enanta To Stop EDP-721 HBV Program ↗

November 19, 2021

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer. The move follows...

Via Benzinga

Enanta Pharmaceuticals to Participate in December Investor Conferences

November 19, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program

November 18, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021

November 15, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor

November 12, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

November 08, 2021

Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ:

Via Benzinga

3 Explosive Biotech Stocks -- Could They Shoot Even Higher? ↗

November 03, 2021

These biotech stocks have recently been responsible for a slew of rocketship emojis.

Via The Motley Fool

What 7 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

October 20, 2021

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ra...

Via Benzinga

Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022 ↗

October 19, 2021

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor for COVID-19. ...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.